Search Results

Biomed Pharmacother. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056 Azam S, Haque ME, Jakaria

In Anesthesiology Neurocrine Biosciences discovers new muscarinic M4 receptor antagonists Alexander S.

and cross-reactivity in tachykinin NK1 and NK2 receptors GPCR Binders, Drugs, and more Discovery of (S)

Saad Hassan , Umut Onur Özcan ,   Jimmy Caroli ,   Albert J Kooistra ,   David E Gloriam ,   Alexander S

receptor negatively modulates substance P responses by forming complex with Neurokinin-1 receptor NTR-1's

J., & Fields, S. (2014).

Hollinger, S. and J.R.

Alessandro Berghella , Brinda K Rana , G Enrico Rovati , Valerie Capra , Caroline M Gorvin , Alexander S Biologie (IECB) in Pessac (Bordeaux) AI-Powered Drug Discovery and Antibody Innovation: DeciBio Q&A with Sean

"Dear Sir or Madam, dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium

in Class B GPCRs, the membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal

S. of. S. Non-traditional roles of G protein-coupled receptors in basic cell biology.

For most researchers, that’s a dead end. For Alessandro Nicoli, it’s an opportunity.

Molecule"; Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal MC4R; Recursion completes Exscientia acquisition, signaling a fresh AI–GPCR chapter; OMass–Genentech deal

The realization that he could ask—and answer—complex biological questions with a computer sealed the deal

We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates

November 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative deal

in VLGR1 have been associated with the human Usher syndrome (USH), the most common form of inherited deaf-blindness

Although they form an ancient signaling system, there is still a great deal of variety in neuropeptides

Development of Precision Medicine Platform Sosei Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year Call for GPCR Papers GPCRs: Signal Transduction.

That leads to premature investment in weak scaffolds or endless tinkering with dead ends. This doesn’t mean an overnight overhaul. It means a commitment to continuous improvement — starting with the highest-friction gaps and working

Dear GPCR Enthusiasts , Get ready for an exciting learning experience with our newly updated Principles

This is the kind of insight that makes the difference between a dead-end program and a well-informed

Premium keeps you oriented and out of avoidable dead-ends. FAQ 🔹 What’s included?  

from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Company of the Year and Financing Deal

Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for 'Deal

Advanced Therapy Showcase in Tokyo, Japan, organized by LINK-J Jounce takes the cash under amended deal

Dear Dr.

Dear GPCR Community, Before diving into this week's news, prepare for an incredible learning journey!

Septerna sells GPCR program to Vertex for $48 million Merck KGgA collaborates with Exscientia plc in deal

antagonists BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals